CN102417482A - 一种奥扎格雷乙酯或奥扎格雷甲酯的合成方法 - Google Patents
一种奥扎格雷乙酯或奥扎格雷甲酯的合成方法 Download PDFInfo
- Publication number
- CN102417482A CN102417482A CN2011104557754A CN201110455775A CN102417482A CN 102417482 A CN102417482 A CN 102417482A CN 2011104557754 A CN2011104557754 A CN 2011104557754A CN 201110455775 A CN201110455775 A CN 201110455775A CN 102417482 A CN102417482 A CN 102417482A
- Authority
- CN
- China
- Prior art keywords
- ozagrel
- brooethyl
- cinnamate
- ethyl ester
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229950003837 ozagrel Drugs 0.000 title claims abstract description 62
- 238000000034 method Methods 0.000 title abstract description 27
- FTLRFDGBBQSQMJ-VOTSOKGWSA-N methyl (e)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoate Chemical compound C1=CC(/C=C/C(=O)OC)=CC=C1CN1C=NC=C1 FTLRFDGBBQSQMJ-VOTSOKGWSA-N 0.000 title abstract 3
- 230000002194 synthesizing effect Effects 0.000 title 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims abstract description 27
- -1 ozagrel methyl esters Chemical class 0.000 claims description 46
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 45
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 39
- 239000012141 concentrate Substances 0.000 claims description 39
- 238000001035 drying Methods 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 34
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 34
- 238000006243 chemical reaction Methods 0.000 claims description 31
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 30
- 238000010438 heat treatment Methods 0.000 claims description 28
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 26
- CCRCUPLGCSFEDV-UHFFFAOYSA-N cinnamic acid methyl ester Natural products COC(=O)C=CC1=CC=CC=C1 CCRCUPLGCSFEDV-UHFFFAOYSA-N 0.000 claims description 25
- CCRCUPLGCSFEDV-BQYQJAHWSA-N methyl trans-cinnamate Chemical compound COC(=O)\C=C\C1=CC=CC=C1 CCRCUPLGCSFEDV-BQYQJAHWSA-N 0.000 claims description 24
- 238000001953 recrystallisation Methods 0.000 claims description 24
- KBEBGUQPQBELIU-CMDGGOBGSA-N Ethyl cinnamate Chemical compound CCOC(=O)\C=C\C1=CC=CC=C1 KBEBGUQPQBELIU-CMDGGOBGSA-N 0.000 claims description 23
- KBEBGUQPQBELIU-UHFFFAOYSA-N cinnamic acid ethyl ester Natural products CCOC(=O)C=CC1=CC=CC=C1 KBEBGUQPQBELIU-UHFFFAOYSA-N 0.000 claims description 23
- 150000002460 imidazoles Chemical class 0.000 claims description 22
- 239000003960 organic solvent Substances 0.000 claims description 22
- 239000000706 filtrate Substances 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 18
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 16
- 238000005406 washing Methods 0.000 claims description 16
- 235000019441 ethanol Nutrition 0.000 claims description 15
- 235000007715 potassium iodide Nutrition 0.000 claims description 15
- 229960004839 potassium iodide Drugs 0.000 claims description 15
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 claims description 15
- 238000010992 reflux Methods 0.000 claims description 15
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 13
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 13
- 239000012074 organic phase Substances 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- SHZKQBHERIJWAO-AATRIKPKSA-N ozagrel Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1CN1C=NC=C1 SHZKQBHERIJWAO-AATRIKPKSA-N 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 6
- ZIRVAUOPXCOSFU-BQYQJAHWSA-N ethyl (e)-3-[4-(bromomethyl)phenyl]prop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CC=C(CBr)C=C1 ZIRVAUOPXCOSFU-BQYQJAHWSA-N 0.000 abstract 2
- ZSRCGGBALFGALF-VOTSOKGWSA-N methyl (e)-3-[4-(bromomethyl)phenyl]prop-2-enoate Chemical compound COC(=O)\C=C\C1=CC=C(CBr)C=C1 ZSRCGGBALFGALF-VOTSOKGWSA-N 0.000 abstract 2
- CUBAAXZFAYBIAI-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yloxy)propanehydrazide Chemical compound NNC(=O)C(C)OC1=CC=C2OCOC2=C1 CUBAAXZFAYBIAI-UHFFFAOYSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000003912 environmental pollution Methods 0.000 abstract 1
- IMKVSWPEZCELRM-CMDGGOBGSA-N ethyl (e)-3-(4-methylphenyl)prop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CC=C(C)C=C1 IMKVSWPEZCELRM-CMDGGOBGSA-N 0.000 abstract 1
- IMKVSWPEZCELRM-UHFFFAOYSA-N ethyl p-methylcinnamate Natural products CCOC(=O)C=CC1=CC=C(C)C=C1 IMKVSWPEZCELRM-UHFFFAOYSA-N 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 230000006837 decompression Effects 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 102000011759 adducin Human genes 0.000 description 4
- 108010076723 adducin Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000007810 chemical reaction solvent Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- NQBWNECTZUOWID-UHFFFAOYSA-N (E)-cinnamyl (E)-cinnamate Natural products C=1C=CC=CC=1C=CC(=O)OCC=CC1=CC=CC=C1 NQBWNECTZUOWID-UHFFFAOYSA-N 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000003725 endotheliocyte Anatomy 0.000 description 2
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 206010013976 Dyspraxia Diseases 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 206010067347 Thrombotic cerebral infarction Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- NQBWNECTZUOWID-QSYVVUFSSA-N cinnamyl cinnamate Chemical compound C=1C=CC=CC=1\C=C/C(=O)OC\C=C\C1=CC=CC=C1 NQBWNECTZUOWID-QSYVVUFSSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110455775 CN102417482B (zh) | 2011-12-31 | 2011-12-31 | 一种奥扎格雷乙酯或奥扎格雷甲酯的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110455775 CN102417482B (zh) | 2011-12-31 | 2011-12-31 | 一种奥扎格雷乙酯或奥扎格雷甲酯的合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102417482A true CN102417482A (zh) | 2012-04-18 |
CN102417482B CN102417482B (zh) | 2013-03-27 |
Family
ID=45942147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110455775 Expired - Fee Related CN102417482B (zh) | 2011-12-31 | 2011-12-31 | 一种奥扎格雷乙酯或奥扎格雷甲酯的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102417482B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104761500A (zh) * | 2014-01-08 | 2015-07-08 | 济南大成医药发展有限公司 | (e)-4-(1-咪唑甲基)肉桂酸甲酯的制备方法 |
CN105418510A (zh) * | 2015-12-29 | 2016-03-23 | 济南诚汇双达化工有限公司 | 一种(e)-4-(咪唑基甲基)肉桂酸甲酯的制备方法 |
CN105481771A (zh) * | 2015-12-29 | 2016-04-13 | 济南诚汇双达化工有限公司 | 一种奥扎格雷中间体(e)-4-(咪唑基甲基)肉桂酸甲酯的制备工艺 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102241632A (zh) * | 2010-05-10 | 2011-11-16 | 辽宁诺康医药有限公司 | 一种奥扎格雷原料药的制备方法 |
-
2011
- 2011-12-31 CN CN 201110455775 patent/CN102417482B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102241632A (zh) * | 2010-05-10 | 2011-11-16 | 辽宁诺康医药有限公司 | 一种奥扎格雷原料药的制备方法 |
Non-Patent Citations (2)
Title |
---|
王道林等: "奥扎格雷钠的合成", 《中国医药工业杂志》 * |
薛叙明等: "奥扎格雷的合成工艺", 《化工进展》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104761500A (zh) * | 2014-01-08 | 2015-07-08 | 济南大成医药发展有限公司 | (e)-4-(1-咪唑甲基)肉桂酸甲酯的制备方法 |
CN104761500B (zh) * | 2014-01-08 | 2017-11-21 | 济南大成医药发展有限公司 | (e)‑4‑(1‑咪唑甲基)肉桂酸甲酯的制备方法 |
CN105418510A (zh) * | 2015-12-29 | 2016-03-23 | 济南诚汇双达化工有限公司 | 一种(e)-4-(咪唑基甲基)肉桂酸甲酯的制备方法 |
CN105481771A (zh) * | 2015-12-29 | 2016-04-13 | 济南诚汇双达化工有限公司 | 一种奥扎格雷中间体(e)-4-(咪唑基甲基)肉桂酸甲酯的制备工艺 |
CN105418510B (zh) * | 2015-12-29 | 2018-05-15 | 济南诚汇双达化工有限公司 | 一种(e)-4-(咪唑基甲基)肉桂酸甲酯的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102417482B (zh) | 2013-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5395908B2 (ja) | 4−(1−ヒドロキシ−1−メチルエチル)−2−プロピルイミダゾール−5−カルボン酸エステルの製造方法 | |
CN107602372B (zh) | 制备脂肪酸的方法 | |
CN105254603A (zh) | 呋喃铵盐的合成工艺 | |
EP1924574A2 (en) | Process for the syntesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine | |
EP0841063A1 (en) | Ketone derivatives and medicinal use thereof | |
CN104130258A (zh) | 一种二聚体的转化方法 | |
CN102558061A (zh) | 一种奥扎格雷合成方法 | |
CN102417482A (zh) | 一种奥扎格雷乙酯或奥扎格雷甲酯的合成方法 | |
CN102351691B (zh) | 一种己二酸单乙酯的合成方法 | |
CN102127060B (zh) | 一种阿托伐他汀钙中间体的制备方法 | |
CN102911128A (zh) | 一种缬沙坦的合成方法 | |
CN103304550B (zh) | 一种奥美沙坦酯的制备方法 | |
CN102702191A (zh) | 长春西汀的合成方法 | |
CN101845070B (zh) | 抗肿瘤药物卡培他滨的合成方法 | |
EA027565B1 (ru) | Способ переэтерификации эфиров ретинола | |
CN101007760A (zh) | 一种不饱和酸酯化方法 | |
CN105693587A (zh) | 一种阿托伐他汀钙的生产工艺 | |
CN101514154A (zh) | 脂肪族α-酮酸钙的合成方法 | |
JP2012524044A (ja) | 2,4,6−オクタトリエン−1−酸及び2,4,6−オクタトリエン−1−オールの調製方法 | |
CN104402745A (zh) | 一种3-氨基巴豆酸异丙酯的合成方法 | |
CN113121354A (zh) | 一种取代联苯化合物的合成方法 | |
CN104276979B (zh) | 阿戈美拉汀中间体的制备方法 | |
CN101781311A (zh) | 一种抗血小板聚集化合物的新型制备方法 | |
WO2011002090A1 (ja) | 脂肪酸低級アルキルエステル、グリセリン及びステリルグリコシドの製造法 | |
CN101434533B (zh) | 一种新型的索法酮制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING YMKY PHARMACEUTICAL TECHNOLOGY CO. LTD. Free format text: FORMER OWNER: TIBET YIMING XIYA BIOPHARMACEUTICAL TECHNOLOGY CO., LTD. Effective date: 20120515 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20120515 Address after: 100098 Beijing city Haidian District Beijing Haidian District No. 48 Zhichun Road Yingdu building B block 22 layer Applicant after: BEIJING YMKY PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Address before: 100098 Beijing city Haidian District No. 48 Zhichun Road Yingdu building B block 22 layer Applicant before: TIBET YIMING XIYA BIOLOGICAL MEDICAL TECHNOLOGY Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 100098 Beijing city Haidian District No. 48 Zhichun Road Yingdu building C-4-15A Patentee after: BEIJING YMKY PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Address before: 100098 Beijing city Haidian District No. 48 Zhichun Road Yingdu building B block 22 layer Patentee before: BEIJING YMKY PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130327 |